New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
March 5, 2024 - The FDA approved Sandoz’s Jubbonti (denosumab-bbdz), biosimilar and interchangeable to Amgen’s Prolia® (denosumab).
Download PDF
Return to publications
